Trametinib DMSO solvate,orb1226854,Biorbyt产品图

Trametinib DMSO solvate,orb122

6854,Biorbyt
收藏
  • ¥0 - 2340
  • Biorbyt已认证
  • 英国
  • orb1226854
  • 2026年08月09日
    avatar
    品牌商
    13钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 保存条件

      详询

    • 保质期

      12 months from date of receipt.

    • 英文名

      Trametinib DMSO solvate

    • 库存

      99

    • 供应商

      Biorbyt

    • CAS号

      1187431-43-1

    • 规格

      500 mg/1 g/10 mg/25 mg/50 mg/100 mg/200 mg

    规格:500 mg产品价格:¥0.0
    规格:1 g产品价格:¥0.0
    规格:10 mg产品价格:¥936.0
    规格:25 mg产品价格:¥1170.0
    规格:50 mg产品价格:¥1287.0
    规格:100 mg产品价格:¥1755.0
    规格:200 mg产品价格:¥2340.0
    类别: Small Molecules

    描述: A potent and highly specific MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM; exhibits no inhibition on the kinase activities of c-Raf, B-Raf, ERK1/2.Skin Cancer Approved(In Vitro):In BRAF mutant SK-MEL-28 cells and KRAS mutant HCT116 cells, Trametinib (GSK1120212;JTP-74057) DMSO solvate causes dose-dependent inhibition of ERK1/2 phosphorylation as well as dose-dependent growth inhibition. In both SK-MEL-28 and HCT116 cells, Trametinib DMSO solvate inhibits 50% p-ERK1/2 at nearly equivalent concentrations (0.8 and 1.8 nM, respectively). However, as the slopes of the curves reflect, in SK-MEL-28 cells, Trametinib DMSO solvate inhibits 90% p-ERK1/2 at a lower concentration (3.4 nM) than in HCT116 (33.3 nM). Furthermore, in both cell lines, 50% growth inhibition is only achieved at concentrations Trametinib DMSO solvate that produces near complete ERK1/2 inhibition (85 and 90%, respectively).\n(In Vivo):Trametinib (GSK1120212;JTP-74057) DMSO solvate is evaluated in vivo in an A549 (KRAS mutant cell line) xenograft model, orally dosing daily for 21 days (qd×21). In this study, near complete tumor growth inhibition is observed at 5.0 and 2.5 mg/kg [92 and 87% tumor growth inhibition (TGI), respectively] and to a lesser degree at 0.5 and 0.1 mg/kg (62 and 58% TGI). Although 5 mg/kg is the maximally tolerated dose (MTD) in this study, 3 mg/kg is the typically observed MTD. Dose-dependent antitumor activity with Trametinib DMSO solvate treatment has been similarly reported for several other KRAS and BRAF mutant tumor models.

    别名: GSK-1120212 DMSO solvate | Trametinib | JTP-74057 | GSK-1120212

    靶点: MEK

    化学名称: N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide compound with (methylsulfinyl)methane (1:1)

    分子式: C28H29FIN5O5S

    分子量: 693.5283

    纯度: >98% (HPLC)

    SMILES: CC1=C2C(C(N(C3CC3)C(N2C4=CC(NC(C)=O)=CC=C4)=O)=O)=C(NC5=C(F)C=C(I)C=C5)N(C)C1=O.CS(C)=O

    溶解度: DMSO: ≥ 69 mg/mL (Need ultrasonic)

    研究领域: Pharmacology & Drug Discovery

    保存条件: Storage temperature: -20°C. Stability: ≥ 2 years

    备注: For research use only.

    产品细节图片1
    Trametinib DMSO solvate

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 基因测不准、PDX 等不及?患者来源类器官(PDTO) 个体化试药,肿瘤科可落地 SCI 方案

      醇、卡铂、多柔比星、奥拉帕利等指南一线药物设置浓度梯度,采用 Titer-Glo 3D 活细胞试剂盒检测活力,计算 AUC 曲线评估药效;纳入 4 例铂敏感 / 铂耐药完整随访患者,体外 PDTO 药敏结果与患者真实肿瘤退缩、CA125 变化完全吻合。 实验设计: ➤药物分组逻辑(贴合 CSCO/NCCN 指南) 一线化疗、靶向、PARP 抑制剂分层设置 7–9 个 4 倍梯度浓度,设置 DMSO 溶剂对照、最大杀伤阳性对照; ➤铺板与给药方案:单细胞消化后 384 孔标准化铺板,每孔 2000–

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1053
    武汉博欧特生物科技有限公司
    2026年08月11日询价
    ¥960
    上海嵘崴达实业有限公司
    2026年02月26日询价
    ¥960
    广州威佳科技有限公司
    2025年07月09日询价
    ¥129
    AmBeed INC
    2026年05月29日询价
    ¥412
    TargetMol中国
    2025年07月16日询价
    Trametinib DMSO solvate,orb1226854,Biorbyt
    ¥0 - 2340